Lung Cancer

A liquid biopsy may be able to predict the efficacy of EGFR-targeted tyrosine kinase inhibitors in patients with non–small cell lung cancer.

Pembrolizumab offers survival advantages at a much lower cost over atezolizumab.

A recent report highlighted the progress made globally in preventing cancer. However, improvements are still needed.

The agent has a high affinity and specificity for interleukin-1 beta.

The results showed that even patients with disease that has spread to the brain should be considered for immunotherapy.

A pooled analysis of safety, efficacy of pembrolizumab in patients 75+ years of age with PD-L1+ NSCLC

NLR appeared to be a significant predictor of overall survival, and also showed a trend in favor of progression-free survival, among patients with stage III locally-advanced non-small cell lung cancer.

Sequential afatinib and osimertinib improved median overall survival by almost 3.5 years in patients with EGFR T790M-positive non-small cell lung cancer, with an even greater benefit seen in those with Del19-positive disease.

Metformin appeared to increase glucose uptake in lung cancer cells, according to results from a phase II trial.

The study found patients with lung cancer referred to palliative care earlier lived longer.

The findings of a new study presented at ESMO may offer a new treatment for non–small cell lung cancer.

Researchers examined how metformin and TKI therapy did in combatting lung cancer.

Several promising drugs for the treatment of lung cancer have been garnering attention over recent years. These new treatments have been highlighted at conferences and are sure to impact the standard of care.

A new study presented at the International Association for the Study of Lung Cancer's 2019 conference may have found a model for lung cancer screening which improves on lung cancer screening guidelines from the U.S. Preventive Services Task Force.

A new study shows patients with advanced non­­­­–small-cell lung cancer have preferences on which chemotherapy side effects they'd prefer to avoid which highlights the importance of incorporating patient preferences into treatment.

In this phase III trial, investigators assessed the clinical efficacy and safety of durvalumab with or without tremelimumab with etoposide and carboplatin or cisplatin chemotherapy followed by durvalumab with or without tremelimumab maintenance therapy compared with EP alone as first-line treatment in extensive-stage small-cell lung cancer.

Video-assisted thoracic surgery (VATS) results in fewer in-hospital complications and a shorter length of stay compared with open surgery in patients with early-stage lung cancer.

In a phase I trial, researchers demonstrated that KRAS inhibitor AMG 510 demonstrated safety and antitumor activity in advanced NSCLC patients.

Combination immunotherapy with nivolumab plus ipilimumab was examined as a first-line therapy for patients with advanced non–small-cell lung cancer. Results were presented at the International Associate for the Study of Lung Cancer 2019 World Conference on Lung Cancer.

Data presented at the International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer suggested tumor mutational burden may not be associated with the efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy.

Little research has been done on these complications commonly found in lung cancer.

Researchers focused on a subset of patients with high tumor mutational burden using a 20-mutation-per-megabase threshold and found significant improvement in progression-free survival and overall survival.

Findings from the upcoming International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer show camrelizumab and chemotherapy showed survival benefits for patients with metastatic or otherwise advanced non-squamous non–small-cell lung cancer.

What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?

A new meta-analysis compared survival in patients with advanced non–small cell lung cancer who received immunotherapy vs those who received chemotherapy.